Health
Immunotherapy drug improves survival over standard chemotherapy for lung cancer patients – News-Medical.Net
The immunotherapy drug atezolizumab improves survival over standard chemotherapy for many patients with newly diagnosed non-small cell lung cancer (NSCLC), acco…
Reviewed by Emily Henderson, B.Sc.Oct 1 2020
The immunotherapy drug atezolizumab improves survival over standard chemotherapy for many patients with newly diagnosed non-small cell lung cancer (NSCLC), according to a new study led by Yale Cancer Center (YCC) researchers.
The findings, from a global randomized phase 3 clinical trial published today in the New England Journal of Medicine, support the U.S. Food and Drug Administration’s approval of the drug for this indication in May.
These are e…
-
Noosa News23 hours agoBanana farmers still salvaging fruit four weeks after ex-Tropical Cyclone Alfred
-
Noosa News23 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites
-
Business23 hours ago1 ASX dividend stock down 43% I’d buy right now
-
Business16 hours agoBell Potter names more of the best ASX 200 stocks to buy in April